%0 Journal Article
%T Patient Preferences in the Treatment of Vaginal Candidiasis
%A Mark G. Martens
%J Open Journal of Obstetrics and Gynecology
%P 1147-1155
%@ 2160-8806
%D 2018
%I Scientific Research Publishing
%R 10.4236/ojog.2018.812116
%X Vulvovaginal
candidiasis (VVC) is one of the most frequent problems facing women and their
healthcare professionals (HCP). It is difficult for providers to understand the
prevalence of VVC because effective over the counter treatments</span></span><span><span><span style=\"font-family:&quot;\"> </span></span></span><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\">(OTC),
are available. It is expected that there are a great many more episodes of VVC
in our patient population, as the frequency of self-treatment</span></span></span><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\">,</span></span></span><span><span><span style=\"font-family:&quot;\"><span style=\"font-family:Verdana;\"> success and satisfaction for those that use OTC products prior to seeing a
womenĄŻs health care provider is unknown. In this study; healthcare providers were
given OTC miconazole/tioconazole units for free distribution to patients for
whom they diagnosed VVC by exam in their offices. Surveys for both HCP and
patients were also distributed to determine the initial or recurrent nature of
their symptoms and their satisfaction with their treatments. 1265 OBGYNs and 1821
NP/CNM/PAs reported on over </span><span style=\"font-family:Verdana;\">19,000 patients
receiving a single complete treatment.</span></span></span></span><span><span><span style=\"font-family:&quot;\"> </span></span></span><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\">Among HCPs, treatment efficacy was the primary
reason for recommending micona</span></span></span><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\">zole/tioconazole.
However, rapid onset of symptom relief, safety vs. fluconazole, patient preference
for the less messy ovule, avoidance with drugs metabolized by the liver, and
resistance to, or failure on, fluconazole were additional reasons noted for
topical preference.</span></span></span><span><span><span style=\"font-family:&quot;\"> </span></span></span><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\">Overall, patient satisfaction (n</span></span></span><span><span><span style=\"font-family:&quot;\"> </span></span></span><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\">=</span></span></span><span><span><span
%K Candidiasis
%K Miconazole
%K Patient Preference
%K Vulvovaginal Yeast Infections
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=87803